Jose L. Go'MEz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jose L. Go'MEz has a total of 283 co-authors. Here are the top co-authors by number of shared publications:
- Naftali Kaminski
Section of Pulmonary, Critical Care and Sleep Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, USA
11 shared publications - Maor Sauler
Yale School of Medicine
10 shared publications - Geoffrey Lowell Chupp
Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA;
9 shared publications - Clemente J. Britto
Section of Pulmonary, Critical Care and Sleep Medicine, Yale School of Medicine, Yale University, New Haven, CT, USA
8 shared publications - Jonas Christian Schupp
Biomedical Research in Endstage and Obstructive Lung Disease Hannover (BREATH), Member of the German Center for Lung Research (DZL), Hannover, Germany
6 shared publications - Xiting Yan
Yale University School of Medicine
6 shared publications
Latest Publications
- Open Access
- 18 May 2026
- Published by BMJ in BMJ Open Respiratory Research
- Vol. 13 (1) , e004003
Integrated molecular networks reveal latent components distinguishing type 2-high and type 2-low asthma
Background: Type 2 inflammation (T2) biomarkers are used to identify T2-low and T2-high endotypes of asthma in the clinic and understanding of these endotypes has helped to improve clinical management of patients. The T2-low asthma endotype remains relatively poorly characterised and these patients have few treatment options. Despite its clinical relevance, this endotype lacks specific biomarkers. Objective: To identify transcriptional and microRNA signatures associated with asthma endotypes. Methods: We studied 88 participants with asthma stratified into T2-high and T2-low asthma by blood eosinophils and/or fractional exhaled nitric oxide. We defined whole-blood microRNA and mRNA profiles for each participant and used Data Integration Analysis for Biomarker discovery using Latent Variable approaches for Omics integration to identify latent components (LCs). The results were validated in two independent cohorts of subjects with asthma, including patient samples taken before and after treatment with benralizumab. Results: The T2-high endotype was the most prevalent (67%, n=55) within the study population. We identified two LCs associated with T2-high and T2-low asthma. LC1 was characterised by eosinophil-derived mRNAs and included multiple T2-low microRNAs. LC2 was associated with both endotypes and non-eosinophilic cell types. Pathway analysis revealed increased representation of taste and smooth muscle pathways in the T2-low endotype. The T2-low microRNA miR-574-3p was enriched in LC1. Furthermore, we found that the LC signatures were present in two independent cohorts and modulated by benralizumab. Conclusions: T2-high and T2-low asthma are distinguished by unique transcriptomic networks and have minimal microRNA overlaps. T2-low asthma was enriched for pathways involved with smooth muscle contraction. The LCs signatures are also modulated by benralizumab.
- 18 May 2026
- Published by BMJ in BMJ Open Respiratory Research
- Vol. 13 (1) , e004003
Open AccessIntegrated molecular networks reveal latent components distinguishing type 2-high and type 2-low asthma
Background: Type 2 inflammation (T2) biomarkers are used to identify T2-low and T2-high endotypes of asthma in the clinic and understanding of these endotypes has helped to improve clinical management of patients. The T2-low asthma endotype remains relatively poorly characterised and these patients have few treatment options. Despite its clinical relevance, this endotype lacks specific biomarkers. Objective: To identify transcriptional and microRNA signatures associated with asthma endotypes. Methods: We studied 88 participants with asthma stratified into T2-high and T2-low asthma by blood eosinophils and/or fractional exhaled nitric oxide. We defined whole-blood microRNA and mRNA profiles for each participant and used Data Integration Analysis for Biomarker discovery using Latent Variable approaches for Omics integration to identify latent components (LCs). The results were validated in two independent cohorts of subjects with asthma, including patient samples taken before and after treatment with benralizumab. Results: The T2-high endotype was the most prevalent (67%, n=55) within the study population. We identified two LCs associated with T2-high and T2-low asthma. LC1 was characterised by eosinophil-derived mRNAs and included multiple T2-low microRNAs. LC2 was associated with both endotypes and non-eosinophilic cell types. Pathway analysis revealed increased representation of taste and smooth muscle pathways in the T2-low endotype. The T2-low microRNA miR-574-3p was enriched in LC1. Furthermore, we found that the LC signatures were present in two independent cohorts and modulated by benralizumab. Conclusions: T2-high and T2-low asthma are distinguished by unique transcriptomic networks and have minimal microRNA overlaps. T2-low asthma was enriched for pathways involved with smooth muscle contraction. The LCs signatures are also modulated by benralizumab.
- 1 December 2025
- Published by Oxford University Press (OUP) in American Journal of Respiratory Cell and Molecular Biology
- Vol. 73 (6) , 884-896
Sex-biased Gene Expression Underlies Immune Dysfunction in Asthma
Asthma prevalence and severity differs between male and female individuals across the lifespan. Prepubescent boys are more likely to experience asthma, but girls are disproportionately affected after puberty, with greater symptom burden and decreased type 2 inflammation. However, because the human male and female genomes are almost identical, it is especially difficult to identify differentially expressed genes by sex to account for differences in disease susceptibility and manifestations without large sample sizes. Although several genes and genetic polymorphisms lead to sex-specific effects in asthma risk, the effects of sex-biased gene expression on clinical features within patients with asthma remain understudied. In this study, we characterized gene expression differences between female and male individuals through meta-analysis of transcriptomes of blood samples from adult patients with and without asthma in a large gene expression database (n = 3,639; 56% female). A separate, local validation cohort (n = 132; 78% female) identified clinical correlations with expression levels of sex-biased expressed genes. We identified 61 genes differentially expressed by sex in circulating immune cells that are unique to adult subjects with asthma and correlate with important clinical features of asthma. These genes are implicated in lymphocyte proliferation and differentiation as well as innate and adaptive immune allergic responses in the lung. In addition, similar transcriptional meta-analyses of pediatric asthma demonstrated age-specific gene expression effects. In summary, our findings support a sex-specific inflammatory architecture in asthma that is associated with differential gene expression in the blood and is age-specific.
- 1 December 2025
- Published by Oxford University Press (OUP) in American Journal of Respiratory Cell and Molecular Biology
- Vol. 73 (6) , 884-896
Sex-biased Gene Expression Underlies Immune Dysfunction in Asthma
Asthma prevalence and severity differs between male and female individuals across the lifespan. Prepubescent boys are more likely to experience asthma, but girls are disproportionately affected after puberty, with greater symptom burden and decreased type 2 inflammation. However, because the human male and female genomes are almost identical, it is especially difficult to identify differentially expressed genes by sex to account for differences in disease susceptibility and manifestations without large sample sizes. Although several genes and genetic polymorphisms lead to sex-specific effects in asthma risk, the effects of sex-biased gene expression on clinical features within patients with asthma remain understudied. In this study, we characterized gene expression differences between female and male individuals through meta-analysis of transcriptomes of blood samples from adult patients with and without asthma in a large gene expression database (n = 3,639; 56% female). A separate, local validation cohort (n = 132; 78% female) identified clinical correlations with expression levels of sex-biased expressed genes. We identified 61 genes differentially expressed by sex in circulating immune cells that are unique to adult subjects with asthma and correlate with important clinical features of asthma. These genes are implicated in lymphocyte proliferation and differentiation as well as innate and adaptive immune allergic responses in the lung. In addition, similar transcriptional meta-analyses of pediatric asthma demonstrated age-specific gene expression effects. In summary, our findings support a sex-specific inflammatory architecture in asthma that is associated with differential gene expression in the blood and is age-specific.
- Open Access
- 15 May 2025
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 66 (2) , 2401564
Cyclic GMP-AMP synthase expression is enhanced in systemic sclerosis-associated interstitial lung disease and stimulates inflammatory myofibroblast activation
Objective: The lungs of patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD) contain inflammatory myofibroblasts that arise in association with fibrotic stimuli and perturbed innate immunity. The cytosolic DNA-binding receptor cyclic GMP-AMP synthase (cGAS) is implicated in inflammation and fibrosis, but its involvement in SSc-ILD remains unknown. We examined cGAS expression, activity and therapeutic potential in SSc-ILD using human biospecimens, cultured fibroblasts, precision-cut lung slices and a well-accepted animal model. Methods: Expression and localisation of cGAS, cytokines and type 1 interferons were evaluated in SSc‑ILD lung tissues, bronchoalveolar lavage fluid and isolated lung fibroblasts. CGAS activation was assessed in a publicly available SSc-ILD single-cell RNA-sequencing dataset. Production of cytokines, type 1 interferons and α-smooth muscle actin elicited by transforming growth factor-β1 or local substrate stiffness was measured in normal human lung fibroblasts via quantitative reverse transcription PCR, ELISA and immunofluorescence. Small molecule cGAS inhibition was tested in cultured fibroblasts, human precision-cut lung slices and the bleomycin pulmonary fibrosis model. Results: SSc-ILD lung tissue and bronchoalveolar lavage fluid were enriched for cGAS, cytokines and type 1 interferons. The cGAS pathway showed constitutive activation in SSc-ILD fibroblasts and was inducible in normal human lung fibroblasts by transforming growth factor-β1 or mechanical stimuli. In these settings, and in precision-cut lung slices, cGAS expression was paralleled by the production of cytokines, type 1 interferons and α-smooth muscle actin, which was mitigated by a small molecule cGAS inhibitor. These findings were recapitulated in the bleomycin mouse model. Conclusion: cGAS signalling contributes to pathogenic inflammatory myofibroblast phenotypes in SSc‑ILD. Inhibiting cGAS or its downstream effectors represents a novel therapeutic approach.
- 15 May 2025
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 66 (2) , 2401564
Open AccessCyclic GMP-AMP synthase expression is enhanced in systemic sclerosis-associated interstitial lung disease and stimulates inflammatory myofibroblast activation
Objective: The lungs of patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD) contain inflammatory myofibroblasts that arise in association with fibrotic stimuli and perturbed innate immunity. The cytosolic DNA-binding receptor cyclic GMP-AMP synthase (cGAS) is implicated in inflammation and fibrosis, but its involvement in SSc-ILD remains unknown. We examined cGAS expression, activity and therapeutic potential in SSc-ILD using human biospecimens, cultured fibroblasts, precision-cut lung slices and a well-accepted animal model. Methods: Expression and localisation of cGAS, cytokines and type 1 interferons were evaluated in SSc‑ILD lung tissues, bronchoalveolar lavage fluid and isolated lung fibroblasts. CGAS activation was assessed in a publicly available SSc-ILD single-cell RNA-sequencing dataset. Production of cytokines, type 1 interferons and α-smooth muscle actin elicited by transforming growth factor-β1 or local substrate stiffness was measured in normal human lung fibroblasts via quantitative reverse transcription PCR, ELISA and immunofluorescence. Small molecule cGAS inhibition was tested in cultured fibroblasts, human precision-cut lung slices and the bleomycin pulmonary fibrosis model. Results: SSc-ILD lung tissue and bronchoalveolar lavage fluid were enriched for cGAS, cytokines and type 1 interferons. The cGAS pathway showed constitutive activation in SSc-ILD fibroblasts and was inducible in normal human lung fibroblasts by transforming growth factor-β1 or mechanical stimuli. In these settings, and in precision-cut lung slices, cGAS expression was paralleled by the production of cytokines, type 1 interferons and α-smooth muscle actin, which was mitigated by a small molecule cGAS inhibitor. These findings were recapitulated in the bleomycin mouse model. Conclusion: cGAS signalling contributes to pathogenic inflammatory myofibroblast phenotypes in SSc‑ILD. Inhibiting cGAS or its downstream effectors represents a novel therapeutic approach.
- 28 January 2025
- Published by American Medical Association (AMA) in JAMA
- Vol. 333 (4) , 293
Uncovering Transcriptional Endotypes in Pediatric Asthma—A New Lens on Biomarker-Based Clinical Stratification
- 28 January 2025
- Published by American Medical Association (AMA) in JAMA
- Vol. 333 (4) , 293
Uncovering Transcriptional Endotypes in Pediatric Asthma—A New Lens on Biomarker-Based Clinical Stratification
- Top Cited Papers
- 15 August 2024
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
- Vol. 210 (4) , 484-496
Single-Cell Profiling Reveals Immune Aberrations in Progressive Idiopathic Pulmonary Fibrosis
Rationale: Changes in peripheral blood cell populations have been observed, but not detailed, at single-cell resolution in idiopathic pulmonary fibrosis (IPF). Objectives: We sought to provide an atlas of the changes in the peripheral immune system in stable and progressive IPF. Methods: Peripheral blood mononuclear cells (PBMCs) from patients with IPF and control subjects were profiled using 10× chromium 5′ single-cell RNA sequencing. Flow cytometry was used for validation. Protein concentrations of regulatory T cells (Tregs) and monocyte chemoattractants were measured in plasma and lung homogenates from patients with IPF and control subjects. Measurements and Main Results: Thirty-eight PBMC samples from 25 patients with IPF and 13 matched control subjects yielded 149,564 cells that segregated into 23 subpopulations. Classical monocytes were increased in patients with progressive and stable IPF compared with control subjects (32.1%, 25.2%, and 17.9%, respectively; P < 0.05). Total lymphocytes were decreased in patients with IPF versus control subjects and in progressive versus stable IPF (52.6% vs. 62.6%, P = 0.035). Tregs were increased in progressive versus stable IPF (1.8% vs. 1.1% of all PBMCs, P = 0.007), although not different than controls, and may be associated with decreased survival (P = 0.009 in Kaplan-Meier analysis; and P = 0.069 after adjusting for age, sex, and baseline FVC). Flow cytometry analysis confirmed this finding in an independent cohort of patients with IPF. The fraction of Tregs out of all T cells was also increased in two cohorts of lung single-cell RNA sequencing. CCL22 and CCL18, ligands for CCR4 and CCR8 Treg chemotaxis receptors, were increased in IPF. Conclusions: The single-cell atlas of the peripheral immune system in IPF reveals an outcome-predictive increase in classical monocytes and Tregs, as well as evidence for a lung–blood immune recruitment axis involving CCL7 (for classical monocytes) and CCL18/CCL22 (for Tregs).
- 15 August 2024
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
- Vol. 210 (4) , 484-496
Top Cited PapersSingle-Cell Profiling Reveals Immune Aberrations in Progressive Idiopathic Pulmonary Fibrosis
Rationale: Changes in peripheral blood cell populations have been observed, but not detailed, at single-cell resolution in idiopathic pulmonary fibrosis (IPF). Objectives: We sought to provide an atlas of the changes in the peripheral immune system in stable and progressive IPF. Methods: Peripheral blood mononuclear cells (PBMCs) from patients with IPF and control subjects were profiled using 10× chromium 5′ single-cell RNA sequencing. Flow cytometry was used for validation. Protein concentrations of regulatory T cells (Tregs) and monocyte chemoattractants were measured in plasma and lung homogenates from patients with IPF and control subjects. Measurements and Main Results: Thirty-eight PBMC samples from 25 patients with IPF and 13 matched control subjects yielded 149,564 cells that segregated into 23 subpopulations. Classical monocytes were increased in patients with progressive and stable IPF compared with control subjects (32.1%, 25.2%, and 17.9%, respectively; P < 0.05). Total lymphocytes were decreased in patients with IPF versus control subjects and in progressive versus stable IPF (52.6% vs. 62.6%, P = 0.035). Tregs were increased in progressive versus stable IPF (1.8% vs. 1.1% of all PBMCs, P = 0.007), although not different than controls, and may be associated with decreased survival (P = 0.009 in Kaplan-Meier analysis; and P = 0.069 after adjusting for age, sex, and baseline FVC). Flow cytometry analysis confirmed this finding in an independent cohort of patients with IPF. The fraction of Tregs out of all T cells was also increased in two cohorts of lung single-cell RNA sequencing. CCL22 and CCL18, ligands for CCR4 and CCR8 Treg chemotaxis receptors, were increased in IPF. Conclusions: The single-cell atlas of the peripheral immune system in IPF reveals an outcome-predictive increase in classical monocytes and Tregs, as well as evidence for a lung–blood immune recruitment axis involving CCL7 (for classical monocytes) and CCL18/CCL22 (for Tregs).
- 1 January 2024
- Published by COPD Foundation in Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation
- Vol. 11 (6) , 611-623
Identification of Severe Acute Exacerbations of Chronic Obstructive Pulmonary Disease Subgroups by Machine Learning Implementation in Electronic Health Records
Rationale: Acute exacerbations of chronic obstructive pulmonary disease (AECOPDs) are heterogeneous. Machine learning (ML) has previously been used to dissect some of the heterogeneity in COPD. The widespread adoption of electronic health records (EHRs) has led to the rapid accumulation of large amounts of patient data as part of routine clinical care. However, it is unclear whether the implementation of ML in EHR-derived data has the potential to identify subgroups of AECOPD. Objectives: To determine whether ML implementation using EHR data from severe AECOPDs requiring hospitalization identifies relevant subgroups. Methods: This study used 2 retrospective cohorts of patients with AECOPDs (non-COVID-19 and COVID-19) treated at Yale- New Haven Hospital. K- means clustering was used to identify patient subgroups. Measurements and Main Results: We identified 3 subgroups in the non-COVID cohort (n=1736). Each subgroup had distinct clinical characteristics. The reference subgroup was the largest (n=904), followed by cardio-renal (n=548) and eosinophilic (n=284). The eosinophilic subgroup had milder severity of AECOPD, including a shorter hospital stay (p<0.01). The cardio-renal subgroup had the highest mortality during (5%) and in the year after hospitalization (30%). Validation of the severe AECOPD classifier in the COVID-19 cohort recapitulated the characteristics seen in the non-COVID cohort. AECOPD subgroups in the COVID-19 cohort had different interleukin (IL)- 1 beta, IL- 2R, and IL- 8 levels (false discovery rate <= 0.05). These specific leukocyte and cytokine profiles resulted in inflammatory differences between the AECOPD subgroups based on C- reactive protein levels. Conclusions: Incorporating ML with EHR data allows the identification of specific clinical and biological subgroups for severe AECOPD.
- 1 January 2024
- Published by COPD Foundation in Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation
- Vol. 11 (6) , 611-623
Identification of Severe Acute Exacerbations of Chronic Obstructive Pulmonary Disease Subgroups by Machine Learning Implementation in Electronic Health Records
Rationale: Acute exacerbations of chronic obstructive pulmonary disease (AECOPDs) are heterogeneous. Machine learning (ML) has previously been used to dissect some of the heterogeneity in COPD. The widespread adoption of electronic health records (EHRs) has led to the rapid accumulation of large amounts of patient data as part of routine clinical care. However, it is unclear whether the implementation of ML in EHR-derived data has the potential to identify subgroups of AECOPD. Objectives: To determine whether ML implementation using EHR data from severe AECOPDs requiring hospitalization identifies relevant subgroups. Methods: This study used 2 retrospective cohorts of patients with AECOPDs (non-COVID-19 and COVID-19) treated at Yale- New Haven Hospital. K- means clustering was used to identify patient subgroups. Measurements and Main Results: We identified 3 subgroups in the non-COVID cohort (n=1736). Each subgroup had distinct clinical characteristics. The reference subgroup was the largest (n=904), followed by cardio-renal (n=548) and eosinophilic (n=284). The eosinophilic subgroup had milder severity of AECOPD, including a shorter hospital stay (p<0.01). The cardio-renal subgroup had the highest mortality during (5%) and in the year after hospitalization (30%). Validation of the severe AECOPD classifier in the COVID-19 cohort recapitulated the characteristics seen in the non-COVID cohort. AECOPD subgroups in the COVID-19 cohort had different interleukin (IL)- 1 beta, IL- 2R, and IL- 8 levels (false discovery rate <= 0.05). These specific leukocyte and cytokine profiles resulted in inflammatory differences between the AECOPD subgroups based on C- reactive protein levels. Conclusions: Incorporating ML with EHR data allows the identification of specific clinical and biological subgroups for severe AECOPD.
- Open Access
- 13 December 2023
- Published by Springer Nature in Respiratory Research
- Vol. 24 (1) , 1-11
Deep learning prediction of hospital readmissions for asthma and COPD
Question: Severe asthma and COPD exacerbations requiring hospitalization are linked to increased disease morbidity and healthcare costs. We sought to identify Electronic Health Record (EHR) features of severe asthma and COPD exacerbations and evaluate the performance of four machine learning (ML) and one deep learning (DL) model in predicting readmissions using EHR data. Study design and methods: Observational study between September 30, 2012, and December 31, 2017, of patients hospitalized with asthma and COPD exacerbations. Results: This study included 5,794 patients, 1,893 with asthma and 3,901 with COPD. Patients with asthma were predominantly female (n = 1288 [68%]), 35% were Black (n = 669), and 25% (n = 479) were Hispanic. Black (44 vs. 33%, p = 0.01) and Hispanic patients (30 vs. 24%, p = 0.02) were more likely to be readmitted for asthma. Similarly, patients with COPD readmissions included a large percentage of Blacks (18 vs. 10%, p < 0.01) and Hispanics (8 vs. 5%, p < 0.01). To identify patients at high risk of readmission index hospitalization data of a subset of 2,682 patients, 777 with asthma and 1,905 with COPD, was analyzed with four ML models, and one DL model. We found that multilayer perceptron, the DL method, had the best sensitivity and specificity compared to the four ML methods implemented in the same dataset. Interpretation: Multilayer perceptron, a deep learning method, had the best performance in predicting asthma and COPD readmissions, demonstrating that EHR and deep learning integration can improve high-risk patient detection.
- 13 December 2023
- Published by Springer Nature in Respiratory Research
- Vol. 24 (1) , 1-11
Open AccessDeep learning prediction of hospital readmissions for asthma and COPD
Question: Severe asthma and COPD exacerbations requiring hospitalization are linked to increased disease morbidity and healthcare costs. We sought to identify Electronic Health Record (EHR) features of severe asthma and COPD exacerbations and evaluate the performance of four machine learning (ML) and one deep learning (DL) model in predicting readmissions using EHR data. Study design and methods: Observational study between September 30, 2012, and December 31, 2017, of patients hospitalized with asthma and COPD exacerbations. Results: This study included 5,794 patients, 1,893 with asthma and 3,901 with COPD. Patients with asthma were predominantly female (n = 1288 [68%]), 35% were Black (n = 669), and 25% (n = 479) were Hispanic. Black (44 vs. 33%, p = 0.01) and Hispanic patients (30 vs. 24%, p = 0.02) were more likely to be readmitted for asthma. Similarly, patients with COPD readmissions included a large percentage of Blacks (18 vs. 10%, p < 0.01) and Hispanics (8 vs. 5%, p < 0.01). To identify patients at high risk of readmission index hospitalization data of a subset of 2,682 patients, 777 with asthma and 1,905 with COPD, was analyzed with four ML models, and one DL model. We found that multilayer perceptron, the DL method, had the best sensitivity and specificity compared to the four ML methods implemented in the same dataset. Interpretation: Multilayer perceptron, a deep learning method, had the best performance in predicting asthma and COPD readmissions, demonstrating that EHR and deep learning integration can improve high-risk patient detection.
- Open Access
- 29 June 2023
- Published by European Respiratory Society (ERS) in ERJ Open Research
- Vol. 9 (4)
Shared genetic architecture of blood eosinophil counts and asthma in UK Biobank
Rationale: Asthma is a complex, heterogeneous disease strongly associated with type 2 inflammation, and blood eosinophil counts guide therapeutic interventions in moderate and severe asthma. Eosinophils are leukocytes involved in type 2 immune responses. Despite these critical associations between asthma and blood eosinophil counts, the shared genetic architecture of these two traits remains unknown. The objective of the present study was to characterise the genetic architecture of blood eosinophil counts and asthma in the UK Biobank.Methods: We performed genome-wide association studies (GWAS) of doctor-diagnosed asthma, blood eosinophil, neutrophil, lymphocyte and monocyte counts in the UK Biobank. Genetic correlation analysis was performed on GWAS results and validated in the Trans-National Asthma Genetic Consortium (TAGC) study of asthma.Results: GWAS of doctor-diagnosed asthma and blood eosinophil counts in the UK Biobank identified 585 and 3429 significant variants, respectively.STAT6, a transcription factor involved in interleukin-4 signalling, was a key shared pathway between asthma and blood eosinophil counts. Genetic correlation analysis demonstrated a positive correlation between doctor-diagnosed asthma and blood eosinophil counts (r=0.38±0.10, correlation±se;p=4.7×10−11). As a validation of this association, we found a similar correlation between TAGC and blood eosinophil counts in the UK Biobank (0.37±0.08, correlation±se;p=1.2×10−6)Conclusions: These findings define the shared genetic architecture between blood eosinophil counts and asthma risk in subjects of European ancestry and point to a genetic link to theSTAT6signalling pathway in these two traits.
- 29 June 2023
- Published by European Respiratory Society (ERS) in ERJ Open Research
- Vol. 9 (4)
Open AccessShared genetic architecture of blood eosinophil counts and asthma in UK Biobank
Rationale: Asthma is a complex, heterogeneous disease strongly associated with type 2 inflammation, and blood eosinophil counts guide therapeutic interventions in moderate and severe asthma. Eosinophils are leukocytes involved in type 2 immune responses. Despite these critical associations between asthma and blood eosinophil counts, the shared genetic architecture of these two traits remains unknown. The objective of the present study was to characterise the genetic architecture of blood eosinophil counts and asthma in the UK Biobank.Methods: We performed genome-wide association studies (GWAS) of doctor-diagnosed asthma, blood eosinophil, neutrophil, lymphocyte and monocyte counts in the UK Biobank. Genetic correlation analysis was performed on GWAS results and validated in the Trans-National Asthma Genetic Consortium (TAGC) study of asthma.Results: GWAS of doctor-diagnosed asthma and blood eosinophil counts in the UK Biobank identified 585 and 3429 significant variants, respectively.STAT6, a transcription factor involved in interleukin-4 signalling, was a key shared pathway between asthma and blood eosinophil counts. Genetic correlation analysis demonstrated a positive correlation between doctor-diagnosed asthma and blood eosinophil counts (r=0.38±0.10, correlation±se;p=4.7×10−11). As a validation of this association, we found a similar correlation between TAGC and blood eosinophil counts in the UK Biobank (0.37±0.08, correlation±se;p=1.2×10−6)Conclusions: These findings define the shared genetic architecture between blood eosinophil counts and asthma risk in subjects of European ancestry and point to a genetic link to theSTAT6signalling pathway in these two traits.
- 1 May 2023
- Published by Oxford University Press (OUP)
- p. A3030
Periostin Induction by MicroRNAs Associated With Neutrophilic Airway Inflammation in Asthma
- 1 May 2023
- Published by Oxford University Press (OUP)
- p. A3030
Periostin Induction by MicroRNAs Associated With Neutrophilic Airway Inflammation in Asthma
- 1 May 2023
- Published by Oxford University Press (OUP)
- p. A4435
Sex-specific Transcriptome Profiles and Cytokine Responses in Cystic Fibrosis Monocytes
- 1 May 2023
- Published by Oxford University Press (OUP)
- p. A4435
Sex-specific Transcriptome Profiles and Cytokine Responses in Cystic Fibrosis Monocytes